S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

$2.59
+0.05 (+1.97%)
(As of 12:15 PM ET)
Today's Range
$2.50
$2.63
50-Day Range
$1.86
$2.95
52-Week Range
$0.53
$3.03
Volume
173,957 shs
Average Volume
713,175 shs
Market Capitalization
$224.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Compugen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
54.4% Upside
$4.00 Price Target
Short Interest
Healthy
2.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Compugen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.02 to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

604th out of 939 stocks

Biological Products, Except Diagnostic Industry

101st out of 154 stocks

CGEN stock logo

About Compugen Stock (NASDAQ:CGEN)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Stock Price History

CGEN Stock News Headlines

Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Compugen: Q4 Earnings Snapshot
Earnings Preview For Compugen
Compugen Stock (NASDAQ:CGEN), Short Interest Report
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
CGEN Mar 2024 7.500 call
CGEN Mar 2024 1.500 put
See More Headlines
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGEN
Employees
68
Year Founded
1993

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+57.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,750,000.00
Pretax Margin
-29.24%

Debt

Sales & Book Value

Annual Sales
$33.46 million
Book Value
$0.76 per share

Miscellaneous

Free Float
78,396,000
Market Cap
$220.01 million
Optionable
Optionable
Beta
2.65

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Anat Cohen-Dayag Ph.D. (Age 57)
    CEO, President & Director
    Comp: $796.52k
  • Dr. Zurit Levine Ph.D. (Age 56)
    Senior Vice President of Technology Innovation
    Comp: $345.7k
  • Dr. Pierre Ferre Ph.D. (Age 47)
    Vice President of Preclinical Development
    Comp: $415.1k
  • Mr. Alberto Sessa (Age 62)
    Chief Financial Officer
  • Dr. Eran Ophir Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Yvonne Naughton
    Head of Investor Relations & Corporate Communications
  • Mr. Eran Ben Dor
    General Counsel & Corporate Secretary
  • Ms. Dorit Amitay (Age 56)
    Vice President of Human Resources
  • Dr. Yaron Turpaz M.B.A. (Age 53)
    Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions
  • Rivka Schwartz
    Vice President Research and Discovery

CGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Compugen stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings
or view top-rated stocks.

What is Compugen's stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Compugen's shares. Their CGEN share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts price targets for CGEN
or view top-rated stocks among Wall Street analysts.

How have CGEN shares performed in 2024?

Compugen's stock was trading at $1.98 at the beginning of the year. Since then, CGEN stock has increased by 30.8% and is now trading at $2.59.
View the best growth stocks for 2024 here
.

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CGEN earnings forecast
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Monday, August, 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. During the same period in the previous year, the company earned ($0.11) earnings per share.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Who are Compugen's major shareholders?

Compugen's stock is owned by many different institutional and retail investors. Top institutional investors include Taylor Frigon Capital Management LLC (2.19%), Sphera Funds Management LTD. (0.89%), UBS Group AG (0.36%), Goldman Sachs Group Inc. (0.14%), Goldman Sachs Group Inc. (0.14%) and Northern Trust Corp (0.13%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners